A Recent FDA RMAT Designation Puts (Nasdaq: ENLV) On Our Radar (Low Float)

On July 13th, 2026, the U.S. Food and Drug Administration

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored A Recent FDA RMAT Designation Puts (Nasdaq: ENLV) On Our Radar (Low Float) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* August 13th Greetings, Friend! On July 13th, 2026, the U.S. Food and Drug Administration quietly handed Enlivex Ltd. (Nasdaq: ENLV) something that very few clinical-stage biotechs receive: a Regenerative Medicine Advanced Therapy (RMAT) designation for its lead asset, Allocetra™, targeting age-related knee osteoarthritis in patients 64 and older. The designation is not merely a regulatory footnote. It opens a direct, accelerated dialogue with the FDA, positions ENLV for a potentially shorter path to market, and validates the clinical story that has been building for two years beneath the surface of the broader biotech conversation. The backdrop here is significant. Knee osteoarthritis affects approximately 24.7Mn Americans today and a staggering 78Mn are expected to carry the diagnosis by 2040. Despite that scale, the FDA and the European Medicines Agency have never approved a single disease-modifying therapy for the condition. Every treatment currently in use masks the pain. None of them actually target the underlying inflammatory cascade driving cartilage destruction. That is the gap Allocetra is designed to close. What makes the timing of this particular moment worth your attention is the convergence happening inside ENLV right now. In the same month the RMAT designation landed, the company completed a 1-for-15 reverse st-ock split (effective July 9th, 2026), tightening its publicly available float to approximately 3.85Mn shares. With a share count that small and a Phase IIb trial already dosing a patient in the United States, market watchers who track low-float biotech names could start asking serious questions about ENLV. The Phase IIa results that supported both the RMAT decision and the FDA's clearance of the Phase IIb Investigational New Drug application are compelling. In the randomized, double-blind, placebo-controlled trial across multiple countries, Allocetra delivered an 80% improvement over placebo in composite pain and function scores at six months in patients aged 60 and older (p=0.02). At three months, that spread was even wider, with a 99% improvement over control (p=0.008). The durability of that effect, sustained without retreatment for at least six months from a single administration, is the clinical feature that sets this program apart. ENLV is structured as what management calls a dual-engine model, pairing the Allocetra clinical program with a prediction markets treasury strategy built around RAIN Protocol on the Arbitrum network. That treasury provided the company with net income of approximately $1.23Bn in FY 2025, driven by appreciation in its RAIN token holdings, and has been positioned by Executive Chairman Shai Novik as a mechanism to reduce the company's dependency on traditional equity dilution. That dynamic gives the clinical program financial runway that most early-stage biotechs simply do not have. In June 2026, ENLV presented its Phase IIa clinical data at the European Alliance of Associations for Rheumatology (EULAR) Congress in London, where Prof. Philip Conaghan delivered an oral presentation of the three-month and six-month outcomes to the leading rheumatology community in Europe. The appearance at EULAR signaled that the medical community could be starting to recognize this program at the highest level of scientific review. With Phase IIb enrollment active and top-line data expected by Q2 or Q3 2027, the pipeline is moving. About The Company: Enlivex Ltd. (Nasdaq: ENLV) Enlivex Ltd. is a Nasdaq-listed company running two strategies in parallel. The first is a clinical-stage immunotherapy program centered on Allocetra, an off-the-shelf, allogeneic cell therapy that reprograms macrophages back to their homeostatic state to resolve chronic inflammation.   The lead indication is age-related primary knee osteoarthritis. The active Phase IIb trial targets 182 patients aged 64 and older across the United States, Denmark, and Poland, with top-line data expected in 2027.   Following the RMAT grant, the FDA requested a Type B meeting to align on Phase IIb design and late-stage development plans. This is an early, structured regulatory dialogue that is rare and valuable at this stage of development. The second strategy is a digital asset treasury built around the RAIN protocol on Arbitrum. By July 18th, 2026, Enlivex held approximately 79.55Bn RAIN tokens valued at roughly $1.1Bn, with a reported unaudited mark-to-market NAV per share of $66.16.   The company also carries an option on 271.37Bn additional tokens at $0.0033 per token, intrinsic value estimated near $2.23Bn as of May 2026. More Report Sources: ENLV Website. ENLV Presentation. 5 Key Potential (Nasdaq: ENLV) Catalysts That Trigger Our Radar 1.) FDA RMAT Designation Unlocks Expedited Regulatory Pathway. On July 13th, 2026, ENLV received Regenerative Medicine Advanced Therapy designation from the FDA, a rare designation that provides early, close interaction with regulators and can materially accelerate development timelines for a company like ENLV moving through a pivotal Phase IIb study. 2.) Phase IIb Trial Now Enrolling U.S. Patients With 2027 Readout. Following its March 2026 IND clearance, ENLV has begun dosing the first U.S. patient in its 182-patient global Phase IIb trial, with top-line data expected by Q2 2027, a potential binary catalyst that could redefine market awareness of ENLV. 3.) A Low Float Means There Could Be Potential For Significantly Heightened Volatility. With a share float of approximately 3.85Mn shares per Yahoo Finance, ENLV qualifies as a low-float name, meaning the potential for heightened volatility is significant, particularly against any potential clinical or regulatory catalyst. 4.) First-Mover Advantage In A Market With Zero Approved DMOADs. Neither the FDA nor the EMA has ever approved a disease-modifying osteoarthritis drug, which means ENLV's Allocetra could be charting territory no other approved therapy has entered, positioning ENLV as a potential first-mover in a multi-Bn-dollar therapeutic category. 5.) Treasury Model Provides Financial Runway Independent of Dilution. ENLV's prediction markets treasury strategy, anchored in RAIN Protocol exposure, generated approximately $1.23Bn in net income in FY 2025, providing ENLV with a non-dilutive financial engine that operates independently of the clinical development timeline. Closing Note Enlivex Ltd. (Nasdaq: ENLV) is not a story built on conjecture. It's built on published clinical data, an FDA designation earned in a category where approvals are historically rare, and a financial structure that gives the clinical program room to breathe. The knee osteoarthritis market is heading toward $9.1Bn by 2034, and right now, no approved disease-modifying therapy exists to serve it. We're kicking-off coverage on Enlivex Ltd. (Nasdaq: ENLV). Be on the lookout for updates heading out soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 08/12/2026 and ending on 08/13/2026 to publicly disseminate information about (ENLV:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the thirty seven thousand five hundred USD funds that TD Media LLC received from a third party named Awareness Consulting Network LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (ENLV:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/enlv-eejgk/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice